Login to Your Account

Medivir Gets $14M Milestone as FDA Approves Simeprevir

By Cormac Sheridan
Staff Writer

Monday, November 25, 2013
Medivir AB pocketed a 10 million (US$13.5 million) milestone from partner Johnson & Johnson following the FDA approval of its hepatitis C virus (HCV) protease inhibitor (PI) simeprevir, which will be marketed as Olysio.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription